Johnson and Johnson has announced its financial results for the third quarter of 2017, during which it delivered a sales total of $19.7 billion (14.95 billion pounds).
This represented a year-on-year increase of 10.3 percent, a strong rate of growth that has allowed the firm to increase its sales guidance for the full year to a range of $76.1 billion to $76.5 billion.
“Johnson and Johnson has achieved strong year-on-year growth during the third quarter of 2017, with key consumer brands contributing to this momentum.“
Consumer sales during the period came to $3.4 billion, representing an increase of 2.9 percent versus the prior year. International consumer product sales helped to offset a dip in performance in the US.
Over-the-counter products, such as the Tylenol analgesic range and the firm's smoking cessation aids, were cited as strong performers, as well as the OGX and Neutrogena beauty brands.
The firm also saw a surge in its pharmaceutical sales during the quarter, while its medical technology division also saw year-on-year growth.
Alex Gorsky, chairman and chief executive officer of Johnson and Johnson, said: "Our dedicated colleagues continue to focus on advancing our pipelines to bring innovative solutions to patients and consumers around the globe."
With over 20 years of experience within the consumer market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current consumer roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Consumer